Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Current Assets (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Current Assets for 9 consecutive years, with $234.7 million as the latest value for Q2 2025.

  • On a quarterly basis, Current Assets changed N/A to $234.7 million in Q2 2025 year-over-year; TTM through Jun 2025 was $234.7 million, a N/A change, with the full-year FY2024 number at $113.8 million, down 3.65% from a year prior.
  • Current Assets was $234.7 million for Q2 2025 at Akebia Therapeutics, up from $203.8 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $365.0 million in Q1 2021 to a low of $100.1 million in Q3 2024.
  • A 5-year average of $215.9 million and a median of $219.2 million in 2025 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: grew 7.12% in 2021, then tumbled 61.57% in 2023.
  • Akebia Therapeutics' Current Assets stood at $271.1 million in 2021, then tumbled by 31.7% to $185.2 million in 2022, then crashed by 36.2% to $118.1 million in 2023, then dropped by 3.65% to $113.8 million in 2024, then skyrocketed by 106.15% to $234.7 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Current Assets are $234.7 million (Q2 2025), $203.8 million (Q1 2025), and $113.8 million (Q4 2024).